JNJ vs MRK — Key Metrics

Metric JNJ (JOHNSON & JOHNSON) MRK (MERCK & CO INC)
Price272.7137.78
Market Cap656.47 Billion339.66 Billion
P/E (TTM)40.82137.78
P/B (Quarterly)7.6118.257
P/S (TTM)6.615.04
Net Profit Margin (TTM)16.23.6
Gross Margin (TTM)67.671.8
ROE (TTM)19.65.3
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

JOHNSON & JOHNSON
vs
 
MERCK & CO INC
 
JOHNSON & JOHNSON
vs
 
MERCK & CO INC
Performance Comparison
AI Model Recommendation
JNJ · JOHNSON & JOHNSON

Outperform

21
UnderperformOutperform
MRK · MERCK & CO INC

Greatly Outperform

82
UnderperformOutperform
Recommendation Summary

Stock JNJ is projected to outperform the market, stock MRK is projected to greatly outperform the market. Upfront Recommendation: MRK.

Financial Metrics
Prices delayed ~15 min
JNJ Metrics MRK
$272.70 Price $137.78
— Market Capitalization —
40.82 Price to Earnings Ratio 137.78
6.61 Price to Sales 5.04
31.88 Price to FCF Ratio 23.03
9.78 Price to Gross Profit 7.03
40.82 Price to R&D 11.04
11.65 Price to Current Assets 8.72

JNJ vs MRK at a glance

Johnson & Johnson (JNJ) and Merck & CO INC (MRK) are both Drug Manufacturers - General companies in the Healthcare sector. JNJ is the larger, at $656.5 billion in market value against $339.7 billion for MRK, about 1.9 times the size.

On trailing-twelve-month figures, JNJ trades at 40.8 times trailing earnings and MRK at 137.8; net profit margins are 16.2% and 3.6%.

The Upfront Investment model currently rates JNJ Outperform and MRK Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.